Advances in Prenatal Cell‐Free DNA Screening for Dominant Monogenic Conditions: A Review of Current Progress and Future Directions in Clinical Implementation
Prenatal Diagnosis · 2025
DOI: 10.1002/pd.6752 ↗At a glance
Übersichtsarbeit in Prenatal Diagnosis, 2025. Written by Jun Liao and 8 co-authors. Institution: Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA. Major MEDLINE topics: Cell-Free Nucleic Acids, Noninvasive Prenatal Testing, Genetic Diseases, Inborn, Prenatal Diagnosis. Cited 4 times so far (Crossref); 45 references. Funded by: National Key Research and Development Program of China.
Abstract (original language)
Prenatal cell‐free DNA (cfDNA) screening has advanced significantly, extending beyond detecting aneuploidies to sub‐chromosomal copy number variations. However, its application for screening dominant single‐gene conditions, often caused by de novo variants, remains underutilized in the general obstetric population. This study reviews recent data and experience on prenatal cfDNA screening for dominant monogenic conditions using multiple‐gene panels, highlighting its potential to enhance early detection and management of genetic disorders. Integrating comprehensive cfDNA screening into routine prenatal care could complement current imaging techniques and standard prenatal cfDNA screening, which may overlook pre‐symptomatic fetuses with dominant monogenic conditions in early gestation. Despite promising initial results, further research is needed to confirm the clinical validity and utility of cfDNA screening for these conditions. Larger and more diverse studies are necessary to assess the broader applicability of this technology. In addition, key challenges such as access, genetic counseling, ethical considerations, and policy development need to be addressed. A comprehensive approach, including rigorous test design, informed consent, and robust counseling, is essential for the successful adoption of expanded cfDNA screening, ultimately improving clinical outcomes.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York, USA.
- Obstetrics and Gynecology Hospital, Fudan University, Shanghai, China.
- Fulgent Genetics, Inc., El Monte, California, USA.
- Monash IVF Genetics, Dulwich, Australia.
- Division of Clinical Genetics, Department of Pediatrics, Columbia University Irving Medical Center, New York, New York, USA.
- Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Hong Kong, China.
ORCID profiles: Brynn Levy, Kwong Wai Choy, Jinglan Zhang
Funding
- National Key Research and Development Program of China
Cite
APA
Liao, J., Xu, N., Gao, H., Hardy, T., Levy, B., Mehta, L., Choy, K. W., Huang, H., & Zhang, J. (2025). Advances in Prenatal Cell‐Free DNA Screening for Dominant Monogenic Conditions: A Review of Current Progress and Future Directions in Clinical Implementation. Prenatal Diagnosis. https://doi.org/10.1002/pd.6752
Vancouver
Liao J, Xu N, Gao H, Hardy T, Levy B, Mehta L, et al. Advances in Prenatal Cell‐Free DNA Screening for Dominant Monogenic Conditions: A Review of Current Progress and Future Directions in Clinical Implementation. Prenatal Diagnosis. 2025. doi:10.1002/pd.6752
BibTeX
@article{Liao2025,
author = {Liao, Jun and Xu, Naixin and Gao, Harry and Hardy, Tristan and Levy, Brynn and Mehta, Lakshmi and Choy, Kwong Wai and Huang, Hefeng and Zhang, Jinglan},
title = {Advances in Prenatal Cell‐Free DNA Screening for Dominant Monogenic Conditions: A Review of Current Progress and Future Directions in Clinical Implementation},
journal = {Prenatal Diagnosis},
year = {2025},
doi = {10.1002/pd.6752}
}
EUVIMED